Evolent Q3 revenue $511M (+45% YoY), adjusted EBITDA $48.7M, raises 2023 guidance

Evolent Health, Inc.

2023-Q3 EPS reported -$0.91 revenue$511,015,000

Revenue $511.0M, up 44.9% YoY; net loss $33.2M (6.5% margin); adjusted EBITDA $48.7M (9.5% margin).
Specialty care revenue grew 80% vs prior year; NIA acquisition contributed ~24% of growth.
Added three new operating partnerships in Q3; total YTD nine vs annual target of six to eight.
Raised mid-point of 2023 revenue and Adjusted EBITDA outlook; confident in $300M run rate by end of 2024.
Total Lives on Platform 78.1M (up from 19.5M YoY); unique members 41.7M (up from 16.6M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evolent Health, Inc. updated its the quarter ended September 30, 2023 guidance (raised).

Period: the quarter ended September 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On November 2, 2023, Evolent Health, Inc. (the " Company ") issued a press release announcing its financial results for the quarter ended September 30, 2023, a copy of which is furnished herewith as Exhibit 99.1.

View on SEC.gov

Browse all earnings releases →

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-23-000162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.